|
Overview |
Product information |
Accredo services |
Contact team
Fabry disease is an inherited condition that affects only a few thousand people worldwide.
People with Fabry disease are missing or have insufficient amounts of the alpha-GAL enzyme, which is important in the healthy functioning of organs. The alpha-GAL enzyme is responsible for removing a fatty substance, GL-3, from cells throughout the body. Without enough of this enzyme, the GL-3 substance builds up in cells. GL-3 build-up in kidney cells may cause severe kidney problems, including kidney failure. Learn more about Fabry disease therapy management.
People with Fabry disease may experience a wide range of signs and symptoms, including severe conditions such as kidney failure, heart problems, and stroke.
Accredo has been working with lysosomal storage disorder (LSD) therapies since 1991 and has gained extensive experience that serves as a valuable resource to our patients.
Referrals
Other Resources:
Fabrazyme.com
Fabry Community
Genzyme Corporation
NORD - National Organization for Rare Diseases
Fabrazyme is a registered trademark of Genzyme Corporation.
| 
